Table 3.
Objective response by mRECIST predicts overall survival: results of RCT
| Study, year | Agents (study design) | ORR (mRECIST), % (n/N) | Median OS, months |
HR (95% CI) | p value | |
|---|---|---|---|---|---|---|
| responder (CR + PR) | nonresponder (SD + PD) | |||||
| Lencioni [8], 2017 | brivanib (Phase III RCT) | 11.5 (26/226) | 15.0 | 9.4 | 0.31 (0.16–0.60) | <0.001 |
| Meyer [9], 2017 | nintedanib + sorafenib (Phase II RCT) | 15.6 (28/180) | 16.7 | 10.9 | 0.544 (0.335–0.881) | 0.0122 |
| Kudo [10], 2018 | sorafenib (Phase III RCT) | 18.8 (18/96) | 27.2 | 8.9 | N/A | <0.001 |
RCT, randomized controlled trial; ORR, objective response rate; OS, overall survival; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; HR, hazard ratio.